Copycat Ozempic makers just lost a big court fight

Court ruling opens door to FDA action against Ozempic compounders

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy. A federal judge on Thursday ruled against a compounding trade group’s request for a preliminary injunction that would have prevented the Food and Drug Administration from taking action against its members for making copies of semaglutide. Compounding pharmacies are…

Copycat Ozempic makers just lost a big court fight

In a win for Novo Nordisk, a judge's ruling stops compounding pharmacies from making cheaper versions of Ozempic and Wegovy

O que podemos esperar da moda após a popularização do Ozempic?

This article is written by a student writer from the Her Campus at Casper Libero chapter. O cuidado com adultos diabéticos do tipo 2, não controlada, representa 10,2% da população, segundo a Sociedade Brasileira de Diabetes (SBD). Graças ao Ozempic, novo medicamento do laboratório Novo Nordisk, pessoas portadoras de diabetes poderão ter uma melhor qualidade de vida. O medicamento GLP-1, que possui a semaglutida como princípio ativo – um composto…

A US judge stops copies of Ozempic and Wegovy. The phenomenon of "compounding" was allowed by the FDA. "Compounding" = pharmacies produce drugs with high demand on their own. Pharmacies could produce the drugs themselves due to shortages. The FDA says there is no longer a shortage of the active ingredient semaglutide. Pharmacies tried to stop the FDA, but the judge did not agree with them. Large pharmacies that produced copies of Ozempic have un…